AbbVie (ABBV) Receivables (2012 - 2026)

AbbVie (ABBV) has reported Receivables for 15 consecutive years, with $13.8 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Receivables rose 9.39% year-over-year to $13.8 billion in Q2 2026; TTM through Jun 2026 was $13.8 billion, a 9.39% increase from a year earlier, with the FY2025 full-year figure at $12.6 billion, up 15.29% from the prior year.
• Receivables was $13.8 billion for Q2 2026 at AbbVie, up from $12.5 billion in the prior quarter.
• Over five years, Receivables peaked at $13.8 billion in Q2 2026 and troughed at $10.7 billion in Q1 2022.
• A 5-year average of $11.8 billion and a median of $11.5 billion in 2023 frame the typical range for Receivables.
• Across the five-year window, Receivables grew 15.75% in 2022 and retreated 2.12% in 2024, its largest moves.
• Over 5 years, Receivables stood at $11.3 billion in 2022, then declined by 0.88% to $11.2 billion in 2023, then decreased by 2.12% to $10.9 billion in 2024, then advanced by 15.29% to $12.6 billion in 2025, then grew by 9.81% to $13.8 billion in 2026.
• The last three Receivables figures came in at $13.8 billion (Q2 2026), $12.5 billion (Q1 2026), and $12.6 billion (Q4 2025), per Business Quant data.